LETTERS TO THE EDITOR

A study on the possible association of dysfunctional uterine bleeding with bacterial vaginosis, mycoplasma, ureaplasma, and *Gardnerella vaginalis*

**Editor,—**A number of studies in the recent years have shown that bacterial vaginosis or its associated micro-organisms mycoplasma/ureaplasma may be associated with various obstetric and gynaecological complications such as pelvic inflammatory disease and infertility,1 premature rupture of membranes and preterm labour,2 plasma cell endometritis,3 non-specific urethritis in male partners,4 and in our previous study5 we showed colonisation of the endometrium by mycoplasma and ureaplasma in patients with bacterial vaginosis.

The purpose of this study was to see if there is any association between dysfunctional uterine bleeding (DUB) and mycoplasma, ureaplasma, and/or bacterial vaginosis.

Ten patients, all with dysfunctional uterine bleeding admitted for abdominal hysterectomy, were recruited for the study. Patients were between 38 and 48 years (mean age 44) and all except one were parous. Appropriate ethics committee approval and informed consents were taken.

A detailed history was taken, particularly obstetrics and gynaecological, and any history of bacterial vaginosis or troublesome vaginal discharge. A preoperative high vaginal swab for microscopic diagnosis of bacterial vaginosis was taken. At operation, the endometrial cavity was opened by splitting the anterior wall of the uterus and an endometrial swab and biopsy were taken for microbial culture and scanning electron microscopy for mycoplasma, ureaplasma, and *Gardnerella vaginalis*.

None of the patient had any history of bacterial vaginosis, troublesome vaginal discharge, or any obstetric or gynaecological complications. Microscopic examination of the high vaginal swabs were all normal except one with possible bacterial vaginosis. Microbial culture and scanning electron microscopy showed no mycoplasma, ureaplasma, or *Gardnerella vaginalis*.

Although there is definite association of colonisation of the endometrium by mycoplasma and ureaplasma in patients with bacterial vaginosis, as we showed in our previous study, this study did not show any association of DUB with bacterial vaginosis, *Gardnerella vaginalis*, mycoplasma, or ureaplasma. Any significant association of DUB and bacterial vaginosis appears unlikely, as the age group of the majority of patients with DUB, as in this study, is also different from the age group for bacterial vaginosis.

A K GHOSH
Department of Gynaecology
Royal Infirmary, Leicester LE1 5WW

A MURRAY
Department of Obstetrics and Gynaecology
Royal Infirmary, Leicester LE1 5WW

**A K GHOSH**
Department of Obstetrics and Gynaecology

**A MURRAY**
Department of Medical Microbiology

---

**Table 1 Table of ethnicity in relation to country of acquisition of HIV, as found in the Leicester genitourinary medicine clinic HIV cohort**

<table>
<thead>
<tr>
<th>Ethnicity</th>
<th>Country of acquisition</th>
<th>Asian</th>
<th>African</th>
<th>White</th>
<th>Total (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Asia</td>
<td>2 (3%)</td>
<td>2 (3%)</td>
<td>2 (3%)</td>
<td>6 (9%)</td>
</tr>
<tr>
<td></td>
<td>Africa</td>
<td>2 (3%)</td>
<td>19 (25%)</td>
<td>2 (3%)</td>
<td>29 (31%)</td>
</tr>
<tr>
<td></td>
<td>UK</td>
<td>8 (3%)</td>
<td>31 (35%)</td>
<td>43 (54%)</td>
<td>82 (60%)</td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td>9%</td>
<td>31%</td>
<td>60%</td>
<td>100%</td>
</tr>
</tbody>
</table>

*Thailand.*
Detection of 14-3-3 brain protein in cerebrospinal fluid of HIV infected patients

EDITOR,—The 14-3-3 proteins are a group of highly conserved proteins involved in intracellular signal transduction. So detection of 14-3-3 brain protein has been described in cerebrospinal fluid (CSF) of patients with transmissible spongiform encephalopathies including both sporadic and variant Creutzfeldt-Jakob disease.1 False positive results have been reported in conditions producing (sub)acute neuronal destruction, including herpes simplex encephalitis, ischaemic stroke, multi-infarct dementia, and paraneoplastic syndromes.1,2 We postulated that 14-3-3 brain protein may be detected in CSF from patients with HIV associated dementia complex (HADC) as this condition is characterised neuropathologically by a giant cell encephalitis, leuconecephalopathy, astroglisis and neuronal loss.

We prospectively studied 17 HIV antibody positive patients (14 men) aged 27–60 (median 37) years, with CD4 counts of 0–220 (median 20) cells x10³/µl, who underwent lumbar puncture for investigation of HADC (six patients), staging of lymphoma (five patients), or investigation of other neurological disorders (two), cervical radiculopathy (one), chronic demyelinating polyradiculopathy (one), CMV encephalitis (one), self limiting headache (one). Of those with HADC, the severity of dementia assessed using Memo-rial Sloan-Kettering criteria,3 was mild in two and moderate in four. The degree of atrophy on cranial magnetic resonance imaging, used as a marker of neuronal loss,3 was mild in four and moderate in two. Clinical details of those with lymphoma are given in table 1. At each lumbar puncture an aliquot of CSF (250 µl) was frozen immediately at −20°C and stored for subsequent 14-3-3 protein analysis.

CSF was routinely processed as described previously.4 Detection of 14-3-3 protein was done without knowledge of the patient's diagnosis, using a technique described by Hsich et al,5 modified to use anti-14-3-3 γ polyclonal rabbit antibody.

In 14 of 17 patients CSF was negative for 14-3-3 protein. Of the three with detectable 14-3-3 protein in CSF, all had lymphoma but only one had CNS disease, the other two had only extraneural disease (table 1). These data, although from a small study population, suggest that detection of 14-3-3 protein in CSF is not useful for diagnosis of HADC. Detectable 14-3-3 protein has previously been reported in a non-HIV infected patient with CNS lymphoma,1 so this observation in our patient is not unique, although brain necrosis from coexisting cerebral toxoplasmosis provides an alternative explanation. Of the two patients with extraneural lymphoma and detectable 14-3-3 protein in CSF, one had EBV DNA in CSF and so was at high risk of developing cerebral lymphoma. This possibility could not be confirmed as necropsy was not performed. In neither of the latter two patients was there a CSF pleocytosis, so contamination by 14-3-3 protein derived from peripheral blood leucocytes is unlikely. In the final case the absence of limbic encephalitis or cerebellar degeneration5 makes it difficult to ascribe the finding to a paraneoplastic process.

R F MILLER
Department of Sexually Transmitted Disease, Royal Free and University College Medical School, Mortimer Market Centre, Mortimer Market, Off Gapper Street, London WC1E 6JJ, UK

J E G GREEN
G GIOVANNONI
E J THOMPSON
Department of Neuroimmunology, Institute of Neurology, National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG

Correspondence to: Dr Miller

Table 1 Clinical features, results of CSF brain protein detection, and outcome in patients with lymphoma

<table>
<thead>
<tr>
<th>Patient</th>
<th>Type of lymphoma</th>
<th>No of lumbar puncture</th>
<th>Interval between lumbar puncture (weeks)</th>
<th>14-3-3 detection</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Primary CNS</td>
<td>1</td>
<td>11</td>
<td>No</td>
<td>Died 2 weeks after second lumbar puncture</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Necropsy showed also cerebral toxoplasmosis</td>
</tr>
<tr>
<td>2</td>
<td>Primary CNS</td>
<td>2</td>
<td>3</td>
<td>Yes</td>
<td>Died 2 weeks after second lumbar puncture</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>No</td>
<td>Necropsy confirmed diagnosis</td>
</tr>
<tr>
<td>3</td>
<td>Primary CNS</td>
<td>2</td>
<td>1</td>
<td>NA</td>
<td>Died 3 weeks later. No necropsy</td>
</tr>
<tr>
<td>4</td>
<td>Systemic, disseminated extraneural</td>
<td>1</td>
<td>NA</td>
<td>No</td>
<td>Died 6 weeks later. Cranial MR scan normal but EBV DNA detected in cell free CSF</td>
</tr>
<tr>
<td>5</td>
<td>Systemic, extra neural</td>
<td>1</td>
<td>NA</td>
<td>Yes</td>
<td>Alive. Cranial MR scan normal. Treated with local RT and HAART. No lymphoma recurrence after 39 months follow up</td>
</tr>
</tbody>
</table>

CNS = central nervous system. NA = not applicable. EBV = Epstein-Barr virus. CSF = cerebrospinal fluid. MR = magnetic resonance. RT = radiotherapy. HAART = highly active antiretroviral therapy.

Hepatitis B vaccination in a high risk MSM population: the need for vaccine education

EDITOR,—Estimates of the prevalence of hepatitis B virus (HBV) markers among men who have sex with men (MSM) vary from 5% to 81%, and the prevalence of HBV surface antigen varies from 1% to 11%.1,2 Despite a safe and effective vaccine against HBV, sexually active MSM are not vaccinated adequately.3 Few empirical data describe the factors associated with HBV vaccination among MSM. We conducted a study to identify correlates of HBV vaccination among MSM that could inform future interventions designed to enhance HBV vaccination.

Data were collected at two male “gay” bars in Birmingham, Alabama, USA, using a brief, self administered questionnaire. Of 130 bar patrons, our sample consisted of 111 re-

...
A catalogue of publications is available online (www.paho.org). The monthly journal of PAHO, the Pan American Journal of Public Health, is also available (subscriptions: pusbvc@tsp.sheridan.com).

Imperial College School of Medicine, Division of Paediatrics, Obstetrics and Gynaecology, symposium on Maternal Mental Health and the Child, 12 October 2000

Further details: Symposium Office, Imperial College School of Medicine, Queen Charlotte’s and Chelsea Hospital, Goldhawk Road, London W6 0XG, UK: tel: (44) (0) 20 8383 3904; fax: (44) (0) 20 8383 8555; email: sympreg@ic.ac.uk.

11th Regional Meeting of International Union against Sexually Transmitted Infections, South East Asian and Western Pacific Branch and 24th National Conference of Indian Association for the Study of Sexually Transmitted Diseases and AIDS, 13–15 October 2000, Chandigarh, India

Further details: Dr Bhushan Kumar, Organising Secretary, 11th Regional Meeting of IUSTI–Asia Pacific (SE Asia and W Pacific Branch), Department of Dermatology, Venerology and Leprosy, PGIMER, Chandigarh – 160 021, India (tel: +91 (0172) 745330; fax: +91 (0172) 744401/745078; email: kumarbhushan@hotmail.com).

New Zealand Venereological Society Conference, Centennial Convention Centre, Palmerston North, New Zealand, 18–20 October 2000

Ka Hikoiia Ka Koreorteo Mo Te Tau Rua Mano (Maori Waka ‘i Tāuiheke 2000).” Further details: Sue Peck, Conference Organiser, SP Conference Management, PO Box 4400, Palmerston North, New Zealand (tel: 64 6 357 1466; fax 64 6 357 1426; email: suepeck@xtra.co.nz).

Imperial College School of Medicine, Division of Paediatrics, Obstetrics and Gynaecology, symposium on Women and Children with HIV and AIDS, 20 October 2000

Further details: Symposium Office, Imperial College School of Medicine, Queen Charlotte’s and Chelsea Hospital, Goldhawk Road, London W6 0XG, UK: tel: (44) (0) 20 8383 3904; fax: (44) (0) 20 8383 8555; email: sympreg@ic.ac.uk.

Imperial College School of Medicine, Division of Paediatrics, Obstetrics and Gynaecology, symposium on key issues in the Care of Women and Gynaecological Cancers (for nurses), 30 October 2000

Further details: Symposium Office, Imperial College School of Medicine, Queen Charlotte’s and Chelsea Hospital, Goldhawk Road, London W6 0XG, UK: tel: (44) (0) 20 8383 3904; fax: (44) (0) 20 8383 8555; email: sympreg@ic.ac.uk.

Consortium of Thai Training Institutes for STDs and AIDS—International Union against Sexually Transmitted Infections and Refresher Course on Sexual Health, Lee Garden Plaza Hotel, Hat Yai, Thailand 24–26 November 2000

Further details: Hat Yai Secretariat, Dr Verapol Chandyeying, Dept of OB-GYN, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkla 90110, Thailand (fax: (66-74) 446 361; email: cvpeapol@ratree.psu.ac.th or Bangkok Secretariat, Dr Thanit Palanuvej, Bangkok Hospital, 189 Sathorn Road, Bangkok 10120, Thailand (fax: (66-2) 286 3013; email: pthanit@email.ksc.net).

Royal Society of Medicine and National Institutes of Health International Conference, RSM, London, 7–8 December 2000

The RSM in London, UK, and the NIH in Bethesda, Maryland, US, are organising an international conference to be held at the RSM on “New trends in HIV management and research.” Further details: Victoria Boswell, Academic Conference Assistant, Royal Society of Medicine (tel: +44 (0) 20 7290 2965; fax: +44 (0) 20 7290 2977; email: victoria.boswell@roycosmed.ac.uk).

International Symposium on Disorders of the Prostate, 21–23 March 2001, Castres, France

Further details: Dr Mike Briley, Scientific Director, Pierre Fabre Medicament, Parc Industriel de la Chartreuse, F-81106 Castres Cedex, France (tel:+33 563 714 501; fax: +33 563 725; email: briley@pierre-fabre.imagenet.fr).

Call for papers—6th European Forum on Quality Improvement in Health Care, 29–31 March 2001, Bologna, Italy

Further details: BMA/BMJ Conference Unit, BMA House, Tavistock Square, London WC1H 9JP, UK (tel: (44) (0) 20 7383 6409; fax: (44) (0) 20 7383 6869; email: quality@bma.org.uk; website: www.quality.bmj.com).


Further details: ECEAR ’2001 Conference Secretary, Division of Retrovirology, NIBSC, Blanche Lane, South Mimms, Potters Bar, Herts, EN6 3QG, UK.

NOTICES

International Herpes Alliance and International Herpes Management Forum

The International Herpes Alliance has introduced a website (www.herpesalliance.org) from which can be downloaded patient information leaflets. Its sister organisation, the International Herpes Management Forum (website: www.IHMF.org) has launched new guidelines on the management of herpesvirus infection in pregnancy at the 9th International Congress on Infectious Disease (ICID) in Buenos Aires.

Pan-American Health Organization, regional office of the World Health Organization

www.sextransinf.com
CORRECTION

The paper by Hughes et al “Comparison of risk factors for four sexually transmitted infections: results from a study of attenders at three genitourinary medicine clinics in England” published in the August issue of STI (2000;76:262–7) contained errors in tables 1 and 2. The correct versions of these tables are published here. The multivariable statistical analyses presented in tables 3 and 4, on which the paper focuses and on which the discussion and conclusions are based, are unaffected by the errors and remain unchanged.

Table 1 Characteristics of patients attending three GUM clinics in England, April 1994 to September 1997

<table>
<thead>
<tr>
<th></th>
<th>Royal Hallamshire, Sheffield (%)</th>
<th>St Thomas’s, London (%)</th>
<th>Mortimer Market Centre (MMC), London (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total attenders</td>
<td>20 334</td>
<td>15 155</td>
<td>15 882</td>
</tr>
<tr>
<td>Sex:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>9 992 (49)</td>
<td>7 969 (53)</td>
<td>8 143 (51)</td>
</tr>
<tr>
<td>Female</td>
<td>10 314 (51)</td>
<td>7 186 (47)</td>
<td>7 569 (48)</td>
</tr>
<tr>
<td>Not recorded</td>
<td>28 (&lt;1)</td>
<td>–</td>
<td>80 (1)</td>
</tr>
<tr>
<td>Age group:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13–15</td>
<td>189 (1)</td>
<td>64 (&lt;1)</td>
<td>20 (&lt;1)</td>
</tr>
<tr>
<td>16–19</td>
<td>2 319 (11)</td>
<td>977 (6)</td>
<td>671 (4)</td>
</tr>
<tr>
<td>20–24</td>
<td>5 672 (28)</td>
<td>3 199 (21)</td>
<td>3 390 (21)</td>
</tr>
<tr>
<td>25–34</td>
<td>7 809 (38)</td>
<td>7 425 (49)</td>
<td>7 658 (48)</td>
</tr>
<tr>
<td>35+</td>
<td>4 254 (21)</td>
<td>3 485 (23)</td>
<td>4 135 (26)</td>
</tr>
<tr>
<td>Not recorded</td>
<td>91 (&lt;1)</td>
<td>5 (&lt;1)</td>
<td>8 (&lt;1)</td>
</tr>
<tr>
<td>Male sexual orientation:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heterosexual</td>
<td>9 181 (92)</td>
<td>6 744 (85)</td>
<td>2 176 (27)</td>
</tr>
<tr>
<td>Homosexual/bisexual</td>
<td>800 (8)</td>
<td>1 174 (15)</td>
<td>1 751 (22)</td>
</tr>
<tr>
<td>Not recorded</td>
<td>11 (&lt;1)</td>
<td>51 (1)</td>
<td>4 216 (52)</td>
</tr>
<tr>
<td>Female sexual orientation:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heterosexual</td>
<td>10 145 (98)</td>
<td>7 057 (98)</td>
<td>4 001 (52)</td>
</tr>
<tr>
<td>Homosexual/bisexual</td>
<td>165 (2)</td>
<td>89 (1)</td>
<td>96 (1)</td>
</tr>
<tr>
<td>Not recorded</td>
<td>4 (&lt;1)</td>
<td>40 (1)</td>
<td>3 562 (47)</td>
</tr>
<tr>
<td>Ethnic group:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>18 014 (89)</td>
<td>8 383 (55)</td>
<td>8 629 (54)</td>
</tr>
<tr>
<td>Black Caribbean</td>
<td>1 038 (5)</td>
<td>4 308 (28)</td>
<td>433 (3)</td>
</tr>
<tr>
<td>Black African</td>
<td>1 401 (1)</td>
<td>1 611 (11)</td>
<td>435 (3)</td>
</tr>
<tr>
<td>Asian</td>
<td>483 (2)</td>
<td>496 (3)</td>
<td>506 (3)</td>
</tr>
<tr>
<td>Other/mixed</td>
<td>297 (1)</td>
<td>357 (2)</td>
<td>498 (3)</td>
</tr>
<tr>
<td>Not recorded</td>
<td>362 (2)</td>
<td></td>
<td>5 381 (34)</td>
</tr>
<tr>
<td>Presenting diagnosis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Genital warts</td>
<td>1 976 (10)</td>
<td>963 (6)</td>
<td>619 (4)</td>
</tr>
<tr>
<td>Genital HSV</td>
<td>548 (3)</td>
<td>433 (3)</td>
<td>265 (2)</td>
</tr>
<tr>
<td>Gonorrhoea</td>
<td>389 (2)</td>
<td>559 (4)</td>
<td>285 (2)</td>
</tr>
<tr>
<td>Chlamydia</td>
<td>2 175 (11)</td>
<td>752 (5)</td>
<td>633 (4)</td>
</tr>
<tr>
<td>Number of partners</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(heterosexuals):</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0–1</td>
<td>10 353 (53)</td>
<td>7 299 (53)</td>
<td>2 897 (47)</td>
</tr>
<tr>
<td>2</td>
<td>5 027 (26)</td>
<td>3 541 (26)</td>
<td>1 611 (26)</td>
</tr>
<tr>
<td>3+</td>
<td>3 043 (14)</td>
<td>2 802 (20)</td>
<td>1 669 (27)</td>
</tr>
<tr>
<td>Not recorded</td>
<td>13 (&lt;1)</td>
<td>159 (1)</td>
<td></td>
</tr>
<tr>
<td>Previous STI:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>5 791 (28)</td>
<td>5 807 (38)</td>
<td>3 483 (22)</td>
</tr>
<tr>
<td>Not recorded</td>
<td>–</td>
<td>3 (&lt;1)</td>
<td>7 533 (47)</td>
</tr>
<tr>
<td>Ever injected drugs</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>361 (2)</td>
<td>228 (2)</td>
<td>145 (1)</td>
</tr>
<tr>
<td>Not recorded</td>
<td>2 (&lt;1)</td>
<td></td>
<td>7 486 (47)</td>
</tr>
<tr>
<td>Commercial sex work (ever):</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>543 (3)</td>
<td>181 (1)</td>
<td></td>
</tr>
<tr>
<td>Not recorded</td>
<td>–</td>
<td>15 155 (100)</td>
<td>7 641 (48)</td>
</tr>
<tr>
<td>Total 51 371</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1 Data for 1 April 1994 to 30 September 1997.
2 Data for 1 April 1994 to 31 December 1996.
3 Data for 1996 only.
4 Includes “black other.”
5 First episode.
6 Uncomplicated infection.
7 Number of partners in past 12 months for Sheffield and St Thomas’s clinics and in past 3 months for MMC (see methods for details).

Table 2 Numbers of attenders diagnosed with first episode genital warts, first episode genital HSV, uncomplicated gonorrhoea and uncomplicated chlamydia, showing concurrent infections, in attenders at three GUM clinics in England, April 1994 to September 1997 (+ = present, − = absent)

<table>
<thead>
<tr>
<th>No of attenders (%)</th>
<th>Warts</th>
<th>HSV</th>
<th>Gonorrhoea</th>
<th>Chlamydia</th>
</tr>
</thead>
<tbody>
<tr>
<td>3320</td>
<td>(6.46)</td>
<td>+</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>3101</td>
<td>(6.04)</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>1184</td>
<td>(2.30)</td>
<td>+</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>957</td>
<td>(1.86)</td>
<td>–</td>
<td>+</td>
<td>–</td>
</tr>
<tr>
<td>233</td>
<td>(0.45)</td>
<td>–</td>
<td>–</td>
<td>+</td>
</tr>
<tr>
<td>187</td>
<td>(0.36)</td>
<td>+</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>28</td>
<td>(0.05)</td>
<td>+</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>21</td>
<td>(0.04)</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>21</td>
<td>(0.04)</td>
<td>+</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>11</td>
<td>(0.02)</td>
<td>–</td>
<td>+</td>
<td>–</td>
</tr>
<tr>
<td>9</td>
<td>(0.02)</td>
<td>–</td>
<td>–</td>
<td>+</td>
</tr>
<tr>
<td>2</td>
<td>(0.00)</td>
<td>–</td>
<td>+</td>
<td>–</td>
</tr>
<tr>
<td>42 297</td>
<td>(82.34)</td>
<td>–</td>
<td>–</td>
<td>+</td>
</tr>
<tr>
<td>Total 51 371</td>
<td>(100)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CURRENT PUBLICATIONS

Selected titles form recent reports published worldwide are arranged in the following sections:

Gonorrhoea

Chlamydia

Candidiasis

Bacterial vaginosis

Trichomoniasis

Syphilis and other treponematoses

Hepatitis

Herpes

Human papillomavirus infection

Cervical cytology and colposcopy

Other sexually transmitted infections

Public health and social aspects

Microbiology and immunology

Dermatology

Miscellaneous

Gonorrhoea

Sexually transmitted disease clinic clients are at risk for subsequent gonorrhoea and chlamydia infections—possible ‘core’ transmitters.

RA GUNN, S FITZGERALD, SO ARAL. Sex Transm Dis 2000;27:543–9

Gonorrhoea among men who have sex with men: outbreak caused by a single genotype of erythromycin-resistant Neisseria gonorrhoeae with a single-base pair deletion in mtrR promoter region.

MS XIA, WH WHITTINGTON, WM SHAPER, KK HOLMES. J Infect Dis 2000;181:2080–2

Amultiplex polymerase chain reaction to differentiate β-lactamase plasmids of Neisseria gonorrhoeae.


A typing system for Neisseria gonorrhoeae based on biotinylated oligonucleotide probes to PIB gene variable regions.


The lipopolysaccharide structures of Salmonella enterica serovar typhi murium and Neisseria gonorrhoeae determine the attachment of human mannose-binding lectin to intact organisms.


Expression of AniA, the major anaerobically induced outer membrane protein of Neisseria gonorrhoeae, provides protection against killing by normal human serum.

Chlamydia

Duration of untreated genital infections with Chlamydia trachomatis—a review of the literature.

Urogenital Chlamydia trachomatis serovars in men and women with a symptomatic or asymptomatic infection: an association with clinical manifestations?

Relationship of hormonal contraception and cervical ectopy as measured by computerized planimetry to chlamydial infection in adolescents.
DL JACOBSON, L PERALTA, M FARMER et al. Sex Transm Dis 2000;27:313–9

Pooling cervical swabs and testing by ligase chain reaction are accurate and cost-saving strategies for diagnosis of Chlamydia trachomatis.

Reproducibility problems with the Abbott Laboratories LCx assay for Chlamydia trachomatis and Neisseria gonorrhoeae.
AM GRONOWSKI, S COPPER, D BAORTO, PR MURRAY. J Clin Microbiol 2000;38:2416–8

An important proportion of genital samples submitted for Chlamydia trachomatis detection by PCR contain small amounts of cellular DNA as measured by β-globin gene amplification.

Effects of estradiol and progestrone on susceptibility and early immune responses to Chlamydia trachomatis infection in the female reproductive tract.
C KAUSCH, F ZHOU, AD MURDIN, CB WIRA. Infect Immun 2000;68:4207–16

Priming with Chlamydia trachomatis major outer membrane protein (MOMP) DNA followed by MOMP ISCOM boosting enhances protection and is associated with increased immunoglobulin A and Th1 cellular immune responses.

Genetic differences in the Chlamydia trachomatis tryptophan synthase σ-subunit can explain variations in serovar pathogenesis.
AC SHAH, G CHRISTIANSEN, P ROPSTORFF, S BIRKELUND. Microbes 2000;2:581–92

Role of hyphal formation in interactions of Candida albicans with endothelial cells.

Measurement of T-cell-derived antigen binding molecules and immunoglobulin G specific to Candida albicans mannan in sera of patients with recurrent vulvovaginal candidiosis.

Evidence for mating of the ‘asexual’ yeast Candida albicans in a mammalian host.
CM HULL, RA RAINIER, AD JOHNSON. Science 2000;289:307–9

Bacterial vaginosis

The Papanicolaou smear: inadequate screening test for bacterial vaginosis during pregnancy.

Identification of a human lactoferrin-binding protein in Gardnerella vaginalis.

Trichomoniasis

A randomized trial of intravaginal nooxygen 9 versus oral metronidazole in the treatment of vaginal trichomoniasis.
NM ANTOSELLI, SJ DEHIL, JW WRIGHT. Am J Obstet Gynecol 2000;182:1008–10

Host and tissue specificity of Trichomonas vaginalis is not mediated by its known adhesion proteins.

18S ribosomal DNA-based PCR for diagnosis of Trichomonas vaginalis.
NM ANTOSELLI, SJ DEHIL, JW WRIGHT. Am J Obstet Gynecol 2000;182:1008–10

Syphilis and other treponematoses

Tracing a syphilis outbreak through cyberspace.
JD KAUSCHNER, W WOLF, L FISCHERPONSE et al. JAMA 2000;284:447–9

Strategies for syphilis prevention—findings from surveys in a high-incidence area.
TA FARLEY, RH KAHAL, G JOHNSON, DA COHEN. Sex Transm Dis 2000;27:305–10

Editorial: syphilis—a barometer of community health.
JN WASSERHEIT. Sex Transm Dis 2000;27:311–2

Use of synthetic cardiolipin and lecithin in the antigen used by the Venerable Disease Research Laboratory Test for serodiagnosis of syphilis.

Comparison of the Serodia Treponema pallidum particle agglutination, Captia syphilis-G and Spiroket Reagin II tests with standard test techniques for diagnosis of syphilis.

Treponema pallidum subsp. pertenue displays pathogenic properties different from those of T pallidum subsp. pallidum.

Hepatitis

Detection of hepatitis C virus in the semen of infected men.
ML LEUZEVILLE, JM KUNSTMANN, M DEALMEIDA et al. Lancet 2000;356:42

JS FELDMAN, H MINKOFF, L LANDESMAN, J DEHOVITZ. Sex Transm Dis 2000;27:338–42

The natural history of hepatitis C virus infection—host, viral and environmental factors.
DL THOMAS, J ASTEMBORSKI, RM RAJ et al. JAMA 2000;284:490–6

Herpes

Herpes simplex virus in the human cornea.
HS DUA. Br J Ophthalmol 2000;84:560

Further evidence from a murine infection model that famciclovir interferes with the establishment of HSV-1 latent infections.
AM THACKRAY, H FIELD. J Antimicrob Chemother 2000;45:825–34

Comparison of virus isolation and various polymerase chain reaction methods in the diagnosis of mucocutaneous herpesvirus infection.

Comparison of a monoclonal antibody-blocking enzyme-linked immunosassay and a strip immunoblot assay for identifying type-specific herpes simplex virus type 2 serological responses.

Long term persistence of herpes simplex virus-specific CD8+ CTL in persons with frequently recurring genital herpes.

Letters, Notices, Correction, Current publications

www.sextransinf.com
Immune protection against HSV-2 in B-cell-deficient mice. 
KL DUDLEY, N BOURNE, RN MILEGAN. Virolology 2000;260:454–63

Decreased vaginal disease in J-chain-deficient mice following herpes simplex type 2 genital infection. 

The role of the UL41 gene of herpes simplex virus type 1 in evasion of non-specific host defence mechanisms during primary infection. 

Difference in incidence of spontaneous mutations between herpes simplex virus types 1 and 2. 

Human papillomavirus infection

Quantitative tests for human papillomavirus. 
C JOHNSTON. Lancet 2000;355:2179

Viral load of human papillomavirus 16 as determinant for development of cervical carcinoma in situ: a nested case-control study. 

Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: a nested case-control study. 

Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. 

Human papillomavirus DNA testing for cervical cancer screening in low-resource settings. 

Human papillomavirus testing in women with mild cytologic atypia. 

Mucosal human papillomavirus types in squamous cell carcinomas of the uterine cervix and subsequently on fingers. 

Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: the age-related patterns for high-risk and low-risk types. 
MV JACOBS, MM WALBOOMERS, PF SNIDERS et al. Int J Cancer 2000;87:221–7

Cervical neoplasia and repeated positivity of human papillomavirus infection in human immunodeficiency virus-seropositive and -seronegative women. 

Genital human papillomavirus infection and associated penile intraepithelial neoplasia in males infected with the human immunodeficiency virus. 

Cost-effectiveness of screening for anal squamous intraepithelial lesions and anal cancer in human immunodeficiency virus-negative homosexual and bisexual men. 

Human papillomavirus infection in atrophic smears—a case report. 
R LUZZATTO, M POLI, M RECKTENVALD, L LUZZATTO. Acta Cytol 2000;44:420–2

Imiquimod: an immune response modulator. 

Correlation between pretreatment levels of interferon response genes and clinical responses to an immune response modulator (Imiquimod) in genital warts. 

Comparison of human papillomavirus types 16, 18 and 6 capsid antibody responses following incident infection. 

Absence of antibody against human papillomavirus type 16 E6 and E7 in patients with cervical cancer is independent of sequence variations. 

A new PCR-based assay amplifies the E6-E7 genes of most mucosal human papillomavirus (HPV). 

The human papillomavirus type 16 E7 oncogene is required for the productive stage of the viral life cycle. 

Cervical lesions are associated with human papillomavirus type 16 intratypic variants that have high transcriptional activity and increases usage of common mammalian codons. 

Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. 

Abnormalities of cornified cell envelopes isolated from human papillomavirus type 11-infected genital epithelium. 
DR BROWN, JF BRYAN. Virolology 2000;276:65–70

Inverse relationship between the expression of the human papillomavirus type 16 transcription factor E2 and virus DNA copy number during the progression of cervical intraepithelial neoplasia. 

8-hydroxyl-2’-deoxyguanosine in cervical cells: correlation with grade of dysplasia and human papillomavirus infection. 

Immune reponses induced by BCG recombinant for human papillomavirus L1 and E7 proteins. 
IA JABBAR, OP PERNANDO, N SALUNDERS et al. Vaccine 2000;18:2444–53

Uneven distribution of HPV 16 E6 prototype and variant (83V) oncoprotein in cervical neoplastic lesions. 

Analysis of relative binding affinity of E7–pRB of human papillomavirus 16 variants using the yeast two-hybrid system. 

The E1 helicase of human papillomavirus type 11 binds to the origin of replication with low sequence specificity. 

Suprabasal expression of the human papillomavirus type 16 oncoproteins in mouse epidermis alters expression of cell cycle regulatory proteins. 

Induction of apoptosis in human papillomavirus-positive cancer cells by peptide aptamers targeting the viral E6 oncoprotein. 

Binding of the human papillomavirus type 16 E7 oncoprotein and the adenosine-associated virus Rep78 major regulatory protein in vitro and in yeast and the potential for downstream effects. 


A functional NF-κB binding site in the human papillomavirus type 16 long control region. 

Identification of domains of the HPV11 E1 protein required for DNA replication in vitro. 
Cervical cytology and colposcopy

Management guidelines for women with normal colposcopy after low grade cervical abnormalities: population study.
GR TEALE, ID MOFFITT, CH MANN, DM LUESLEY. BJM 2000;320:1693–6

Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systemic review.

The borderline cervical smear: colposcopic and biopsy outcome.

Combined Pap smear, cervicography and HPV DNA testing in the detection of cervical intraepithelial neoplasia and cancer.

Comparison of endocervical curettage and endocervical brushing.

Laser scanning confocal microscopy of cervical tissue before and after application of acetic acid.

Cervical intraepithelial neoplasia outcomes after large loop excision with clear margins.

Cyclin E expression and early cervical neoplasia in ThinPrep specimens—a feasibility study.

Other sexually transmitted infections

Features of urethritis in a cohort of male soldiers.

High prevalence of Epstein-Barr virus type 2 among homosexual men is caused by sexual transmission.

Seropositivity to human herpesvirus 8 in relation to sexual history and risk of sexually transmitted infections among women.

Public health and social aspects

JP DODDS, L NARDONE, D MERCEY et al. BMJ 2000;320:1510

Promotion of condom use in a high-risk setting in Nicaragua: a randomized controlled trial.

A randomized trial of hierarchical counselling in a short, clinic-based intervention to reduce the risk of sexually transmitted diseases in women.
EL GOLLUB, J FRENCH, A LOUDOU et al. AIDS 2000;14:1249–56

Microbiology and immunology

Role played by lactobacilli in controlling the population of vaginal pathogens.
S BORIS, C BARBES. Microbes Infect 2000;2:543–6

The immune responses to bacterial antigens encountering in vivo at mucosal surfaces.

Dermatology

Vulvitis circumscripta plasmacellularis mimicking child abuse.

Two cases of vulval pigmented extramammary Paget’s disease: histochemical and immunohistochemical studies.

Syndromic treatment of sexually transmitted diseases reduces the proportion of incident HIV infections attributable to these diseases in rural Tanzania.
KK ORROTH, A GAVOLE, J TIODD et al. AIDS 2000;14:1429–38

Control of sexually transmitted diseases for HIV-1 prevention: understanding the implications of the Mwanza and Rakai trials.

Sexually transmitted diseases and the increased risk for HIV transmission: implications for cost-effectiveness analyses of sexually transmitted disease prevention interventions.
HW CHESSON, SD PINKERTON. J Acq Immun Defic Synd 2000;24:48–56

The challenge of sexually transmitted diseases for the military: what has changed?

Reducing risk of sexually transmitted disease and human immunodeficiency virus infection in a military STD clinic: evaluation of a randomised preventive intervention trial.

Assessing the burden of sexual and reproductive ill-health: questions regarding the use of disability-adjusted life years.

Integration of prevention and care of sexually transmitted infections with family planning services: what is the evidence for public health benefits?

Emergency contraception: advance provision in a young, high-risk clinic population.

Prevalence of home pregnancy testing among adolescents.

Sexually transmitted diseases and sexual behaviour in men attending an outpatient’s clinic for gay men in Gothenburg, Sweden.
MAD CHRISTIANSEN, GB NORMAN. Acta Derm Venereol 2000;80:136–9

Adverse childhood experiences and sexually transmitted diseases in men and women: a retrospective study.
SD HILLS, RF ANDA, VJ FILITTI, D NORDENBERG, FA MARCHBANKS. Pediatrics 2000;106:U12–U17

Identification of female cells in postcoital penile swabs using fluorescence in situ hybridisation—application in sexual assault.
KA COLLINS, SJ CINA, MJ PETTIT. Arch Pathol Lab Med 2000;124:1080–2
Fluctuation in lower urinary tract symptoms in women—reassurance and watchful waiting can prevent overtreatment.
SHUNSKAAR. BMJ 2000;320:1418

Incidence and remission rates of lower urinary tract symptoms at one year in women aged 40–60: longitudinal study.

Effect of a three month course of ciprofloxacin on the outcome of reactive arthritis.

Reactive arthritis: the result of an anti-idiotypic immune response to a bacterial lipopolysaccharide antigen where the idiotype has the immunological appearance of a synovial antigen.

Detection of Kaposi’s sarcoma-associated herpesvirus in oral and genital secretions of Zimbabwean women.

Effect of intravaginal practices on the vaginal and cervical mucosa of Zambian women.

Polyherbal formulations with wide spectrum antimicrobial activity against reproductive tract infections and sexually transmitted pathogens.

Bacteriology and treatment of malodorous lower reproductive tract in gynaecologic cancer patients.

Association of Ureaplasma urealyticum with abnormal reactive oxygen species levels and absence of leukocytespermia.

Acute vulvar vestibulitis occurring during chemotherapy with cryptophycin analogue LY355703.
TM DEPAS, M MANDALA, G CURIGLIANO, F PECCA-TORI. Obstet Gynecol 2000;95:1030

Drug therapy: erectile dysfunction.

Effect of erectile dysfunction on frequency of intercourse: a population based prevalence study in Finland.
J KOSKIMAKI, M HAKAMA, H HUHTALA, TLJ TAMMLEA. J Urol 2000;164:367–70

Peyronie’s disease: etiology, medical and surgical therapy.

Evidence based assessment of long-term results of plaque incision and vein grafting for Peyronie’s disease.

Safety and acceptability of a baggy latex condom.

Tuberculosis of the penis after intravesical bacillus Calmette-Guerin treatment.
JM LATINI, DS WANG, P FORGACS, W BEHRLE. J Urol 2000;163:1870

Clinical management of foreign bodies of the genitourinary tract.

Genital diseases in the Peruvian dusky dolphin (Lagenorhynchus obscurus).
MF VANBRESSEM, K VANWAERBEKE, U SIEBERT et al. J Comparative Pathol 2000;122:266–77

Scrotal dog bites.
JM CUMMINGS, J BOUILLER. J Urol 2000;164:57–8